Dr. Francisco Dasí Fernández

Principal Investigator
Research Group on Rare Respiratory Diseases (RRD)


Dr. Francisco Dasí Fernández. Degree in Biology and PhD in Pharmacology from the Universitat de València with outstanding cum laude qualification unanimously. In 2007, he joined the Miguel Servet program of the Instituto de Salud Carlos III (ISCIII) to develop his research work at the Fundación para la Investigación del Hospital Clínico Universitario de València-Instituto de Investigación Sanitaria INCLIVA. In 2013, the ISCIII rated his research work as positive, and, at present, he is a researcher within the IIS INCLIVA, where he leads the Group of Respiratory Rare Diseases. He is an associate professor of the Department of Physiology of the Faculty of Medicine of the University of Valencia.

He has supervised 10 doctoral theses, all of them with the qualification of outstanding cum laude and 15 Master and Degree Final Projects. His line of research focuses on the study of the pathophysiology of alpha-1 antitrypsin deficiency and primary ciliary dyskinesia syndrome, more specifically, in the search for diagnostic and prognostic biomarkers, as well as advanced techniques for the correction of the genes involved in these pathologies (gene therapy and CRISPR/Cas9). He has published 62 articles in indexed journals. He has participated as a speaker in 87 national and international congresses. He is the author of 5 chapters of research, teaching, and informative books, two of which are guides for patients and relatives with alpha-1 antitrypsin deficiency. He has participated as principal investigator (10) and as a collaborating investigator (20) in 30 research projects funded by the national plan (ISCIII and SAF), the Autonomous Community of Valencia, and various Medical Societies. He has participated in the organizing committee of 7 national and international congresses. He has made three research stays in centers of international prestige, of which he maintains collaboration with the Karolinska Institutet, in Stockholm, Sweden, and the Lineberger Cancer Center in North Carolina, USA. He has obtained a total of 13 grants (6 predoctoral and 7 postdoctoral). For his research work, he has received 5 research awards.

Currently, and since 2012, he is the coordinator of the transversal line of Rare Diseases of INCLIVA and scientific advisor of the patient’s association Alfa-1 Spain, of the National Registry of Patients with alpha-1 antitrypsin deficiency (REDAAT) and the Lovexair Foundation. Since 2013, he has been a member of the Research Ethics Committee of the Hospital Clínico de Valencia, scientific advisor of the Scientific Culture and Innovation Unit of the Universitat de València, and coordinator of the working group on Rare Diseases of the Vice-Rectorate of Culture of the University of Valencia. He is an editor in several international scientific journals and an evaluator of the National Agency for Quality Assessment and Accreditation-ANECA. In 2015, he joined the European research group on Primary Ciliary Dyskinesia (eCOST BEAT-PCD as an alternate Spanish representative).

Dr. Francisco Dasí Fernández
Dr. Francisco Dasí Fernández


Redox Imbalance in Nasal Epithelial Cells of Primary Ciliary Dyskinesia Patients. Reula A, Castillo-Corullon S, Armengot M, Herrera G, Escribano A, Dasi F. Antioxidants. 2024 Feb 2;13(2):190. doi: 10.3390/antiox13020190. PMID: 38397788

Alpha-1 antitrypsin deficiency. Dasi F. Medicina Clinica. 2023 Mar 10;160(5):203-205. doi: 10.1016/j.medcli.2022.09.001. PMID: 36253208

Alpha-1 antitrypsin deficiency. Dasi F. Medicina Clínica. 2023 Nov 21:S0025-7753(23)00648-6. doi: 10.1016/j.medcli.2023.10.014. PMID: 37993348

Hypoxia enhances oxidative stress in neutrophils from ZZ Alpha-1 antitrypsin deficiency patients. Magallon M, Castillo-Corullon S, Banuls L, Pellicer D, Romero T, Martinez-Ferraro C, Navarro-Garcia M, Herrejon A, Gonzalez C, Dasi F. Antioxidants. 2023 Apr 3;12(4):872. doi: 10.3390/antiox12040872. PMID: 37107247

Response to the letter to the editor Alpha-1 antitrypsin deficiency: impact of its relevance in hematology. Dasi F. Medicina Clinica. 2023 Oct 11:S0025-7753(23)00528-6. doi: 10.1016/j.medcli.2023.08.005. PMID: 37833107

Implementation of a Gene Panel for Genetic Diagnosis of Primary Ciliary Dyskinesia. Baz-Redon N, Rovira-Amigo S, Paramonov I, Castillo Corullon S, Cols Roig M, Antolin M, Garcia Arumi E, Torrent-Vernetta A, De Mir Messa I, Gartner S, Iglesias Serrano I, Caballero-Rabasco M, Asensio De La Cruz O, Vizmanos-Lamotte G, Martin De Vicente C, Martinez-Colls M, Reula Martin A, Escribano Montaner A, Dasí Fernández F, Armengot Carceller M, Polverino E, Amengual Pieras E, Amaro-Rodriguez R, Garrido-Pontnou M, Tizzano E, Camats-Tarruella N, Fernandez-Cancio M, Moreno-Galdo A. Archivos de Bronconeumologia. 2021 Mar;57(3):186-194. doi: 10.1016/j.arbres.2020.02.010. PMID: 32253119

Methodologies for the determination of blood Alpha1 antitrypsin levels: a systematic review. Ruiz-Duque B, Banuls L, Reinoso-Arija R, Carrasco-Hernandez L, Caballero-Eraso C, Dasi F, Lopez-Campos JL. Journal of Clinical Medicine. 2021 Oct 31;10(21):5132. doi: 10.3390/jcm10215132. PMID: 34768650

New laboratory protocol to determine the oxidative stress profile of human nasal epithelial cells using flow cytometry. Reula A, Pellicer D, Castillo S, Magallon M, Armengot M, Herrera G, O’Connor J, Banuls L, Navarro-Garcia M, Escribano A, Dasi F. Journal of Clinical Medicine. 2021 Mar 11;10(6):1172. doi: 10.3390/jcm10061172. PMID: 33799667

Oxidative stress and endoplasmic reticulum stress in rare respiratory diseases. Magallon M, Carrion A, Banuls L, Pellicer D, Castillo S, Bondia S, Navarro-Garcia M, Gonzalez C, Dasi F. Journal of Clinical Medicine. 2021 Mar 18;10(6):1268. doi: 10.3390/jcm10061268. PMID: 33803835

Prevention of teratogenesis in pregnancies of obese rats by vitamin E supplementation. Alcala M, Bolado V, Sanchez-Vera I, Clapes S, Dasi F, Saez G, Carrera E, Alvarez-Gallego F, Loeken M, Viana M. Antioxidants. 2021 Jul 23;10(8):1173. doi: 10.3390/antiox10081173. PMID: 34439421

Reference: PI17/01250
Title: Estudio del efecto de la hipoxia en la degranulación, producción de citoquinas y perfil oxidativo de neutrófilos de pacientes con déficit de alfa-1 antitripsina
Funding body: Instituto de Salud Carlos III – Cofinanciado FEDER
Principal Investigator: Francisco Dasí Fernández
Duration: 2018 – 2021
Total budget: 99.220 €
+ Info
Title: Efecto de la hipoxia en la degranulación, producción de citoquinas y perfil oxidativo de neutrófilos en pacientes con déficit de alfa-1 antitripsina
Doctoral candidate: Magallón Serrano, María
Director(s): Dasí Fernández, Francisco
Date of the defense: 01/12/2022
University: Universitat de València

Title: Estudio de la utilidad clínica de los microarns en suero y orina de pacientes con cáncer de vejiga
Doctoral candidate: Castelló Porcar, Ana María
Director(s): Dasi Fernandez, Francisco Jose; Martínez Jabaloyas, Jose M
Date of the defense: 27/10/2022
University: Universitat de València

Title: Edición génica del gen serpina1 mediante el uso de CRISPR/CAS9 en células sanguíneas de pacientes con déficit de alfa-1 antitripsina
Doctoral candidate: Bañuls Soto, Lucía
Director(s): Dasí Fernández, Francisco; Escribano Montaner, Amparo; Martí Pérez, Salvador
Date of the defense: 20/05/2022
University: Universitat de València

Title: Valor pronóstico del estudio del perfil de miRNAs en la Neumonía Adquirida en la Comunidad
Doctoral candidate: Vicente Ferrer, Silvia
Director(s): Fernández Fabrellas, Estrella; Sanz Herrero, Francisco; Dasí Fernández, Francisco Jose
Date of the defense: 07/05/2021
University: Universitat de València